A 74-year-old patient with heart failure and atrial fibrillation requires long-term management. Which therapy is most important to reduce stroke risk?

• A. Verapamil (Calan)
• B. Amiodarone (Cordarone)
• C. Furosemide (Lasix)
• D. Warfarin (Coumadin)

Answer: (D)

In atrial fibrillation, the irregular heartbeat causes blood to pool in the left atrium, especially the left atrial appendage, increasing the chance of forming clots that can travel to the brain and trigger a stroke. The main way to lower this risk long term is anticoagulation therapy. Warfarin works as a vitamin K antagonist, reducing the production of several clotting factors (II, VII, IX, X) and thereby decreasing thrombin formation. This mechanism directly lowers the likelihood that a clot will travel to the brain, providing strong protection against ischemic stroke in patients with AF and additional risk factors such as heart failure and advanced age. It’s the standard long-term preventive strategy in this scenario, though it requires regular INR monitoring to keep the dose in the therapeutic range and to balance bleeding risk.

The other options address different goals: rate control with verapamil helps the heart’s rhythm but doesn’t prevent strokes by itself; rhythm-control therapy like amiodarone aims to maintain normal rhythm but also doesn’t by itself reduce stroke risk without anticoagulation; furosemide alleviates fluid overload in heart failure but has no role in lowering stroke risk.